Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Asmacure closes US$9 million Series A financing

Reading Time 1 minute read Subscribe




On May 8, 2007, Asmacure Ltée announced that it had closed a Series A round of financing of US$9 million utilizing an exchangeable shares structure involving Fonds Bio-Innovation and Innovatech Québec Chaudière-Appalaches from Québec City, and Domain Associates from Princeton, New Jersey. This investment will support Asmacure's operations and R & D program through the preclinical and initial clinical development of its Lead Compound aimed at a new pharmacological approach for the treatment of asthma. Asmacure was advised in this financing by a team from Fasken Martineau led by François Duchesneau and that included, among others, René Roy, Marie Carole Tétrault and Jean-Gabriel L'Ecuyer in Québec City and Martin Fisher-Haydis in Toronto.



    Receive email updates from our team